Inhibition of Mammalian Target of Rapamycin Is Required for Optimal Antitumor Effect of HER2 Inhibitors against HER2-Overexpressing Cancer Cells - Concepedia

Concepedia

Publication | Open Access

Inhibition of Mammalian Target of Rapamycin Is Required for Optimal Antitumor Effect of HER2 Inhibitors against HER2-Overexpressing Cancer Cells

DOI Full Paper Access

131

Citations

45

References

2009

Year

Todd W. Miller, James T. Forbes, Chirayu Shah, Shelby K. Wyatt, H. Charles Manning, Maria G. Olivares, Violeta Sánchez, Teresa C. Dugger, Nara de Matos Granja, Archana Narasanna,

Clinical Cancer Research

Abstract

Inhibition of PI3K and mTOR are required for the growth-inhibitory effect of HER2 antagonists. These findings collectively support the combined use of trastuzumab and mTOR inhibitors for the treatment of HER2(+) breast cancer.

References

	Year	Citations
Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/<i>neu</i>Oncogene Dennis J. Slamon, Gary M. Clark, Steven Wong, Science	1987	11.6K
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 Dennis J. Slamon, Brian Leyland‐Jones, Steven Shak, New England Journal of Medicine	2001	11.4K
Studies of the HER-2/ <i>neu</i> Proto-Oncogene in Human Breast and Ovarian Cancer Dennis J. Slamon, William Godolphin, Lovell A. Jones, Science	1989	6.8K
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer Edward H. Romond, Edith A. Perez, John Bryant, New England Journal of Medicine	2005	5.3K
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer Martine Piccart, Marion Procter, Brian Leyland‐Jones, New England Journal of Medicine	2005	5.1K
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Robert J. Motzer, Bernard Escudier, Stéphane Oudard, The Lancet UrologySurgical OncologyGenitourinary CancerMedicineCancer Treatment	2008	3K
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease Melody Cobleigh, Charles L. Vogel, Debu Tripathy, Journal of Clinical Oncology	1999	2.8K
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets Raphael Clynes, Terri L. Towers, Leonard G. Presta, Nature Medicine MedicineInhibitory Fc ReceptorsTumor TargetingAnti-cancer AgentPharmacology	2000	2.7K
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt Kathryn O’Reilly, F. Rojo, Qing‐Bai She, Cancer Research	2006	2.5K
Humanization of an anti-p185HER2 antibody for human cancer therapy. Paul Carter, Leonard G. Presta, C Gorman, Proceedings of the National Academy of Sciences Anti-p185her2 AntibodyTumor TargetingImmunologyHumab4d5-1 VariantAntibody Engineering	1992	1.9K

Page 1